2,4-thiazolidinedione clinical trials
How each study uses 2,4-thiazolidinedione is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Thiazolidinedione
- 4
Studies by the year they started
4 studies that test it; most in 2001 (1)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2005 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Stanford University (1) · GlaxoSmithKline (1) · University of Wisconsin, Madison (1) · Sanofi (1)
Often tested with
Tested in the same studies.
Sulfonylurea Antidiabetic Agent (1) · N,N''-sulfonylbis-urea (1) · Biguanides (1) · Alpha-glucosidase inhibitors (1) · Insulin Glargine (1) · Metformin (1)
Related medicines
As reviewed, each with the page that says it.
- One of Hypoglycemic Agents source
Studies
Open first, then newest update. How each study uses 2,4-thiazolidinedione is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Integrating the Genetic and Metabolic Faces of ObesityCompletedPhase 1Stanford UniversityNCT00285844Written as thiazolidinedione
- A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes MellitusCompletedPhase 3GlaxoSmithKlineNCT01777282Written as Thiazolidinedione
- Islet Transplantation in Type 1 Diabetic PatientsCompletedPhase 1University of Wisconsin, MadisonNCT00214253Written as Thiazolidinedione
- Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other TreatmentCompletedPhase 3SanofiNCT00046462Written as Thiazolidinedione
Given beside what is tested · 3 — 2,4-thiazolidinedione is usual care or a partner of the new treatment
- Add-on to Thiazolidinedione (TZD) FailuresCompletedPhase 3AstraZenecaNCT00683878Written as Thiazolidinedione (Pioglitazone)
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin GlargineCompletedPhase 3SanofiNCT00975286Written as Thiazolidinedione (TZD)
- A Study of LY2189265 in Japanese Participants With Type 2 Diabetes MellitusCompletedPhase 3Eli Lilly and CompanyNCT01468181Written as Thiazolidinedione (TZD)
As the comparator · 1 — what is tested is compared with 2,4-thiazolidinedione
Codes
What other systems call 2,4-thiazolidinedione · ClinicalTrials.gg INT003805
- MeSH (NLM) C0899462,4-thiazolidinedioneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) AA68LXK93C2,4-THIAZOLIDINEDIONEConfirmed NLM, Wikidata
- Wikidata Q13935562,4-thiazolidinedioneConfirmed NLM, Wikidata
- DrugBank DB11898One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C089946 | 2,4-thiazolidinedione | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | AA68LXK93C | 2,4-THIAZOLIDINEDIONE | Confirmed NLM, Wikidata |
| Wikidata | Q1393556 | 2,4-thiazolidinedione | Confirmed NLM, Wikidata |
| DrugBank | DB11898 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.